


Public Health Service



8538 "03 MOV 20 A9:37

Re: Elitek

Docket No. 03E-0249

The Honorable James E. Rogan
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

MAY 18 2003

Dear Director Rogan:

This is in regard to the application for patent term extension for U.S. Patent No. 5,382,518 filed by Sanofi-Synthelabo under 35 U.S.C. § 156. The human biological product claimed by the patent is Elitek (rasburicase), which was assigned BLA No. 103946/0.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in Glaxo Operations UK Ltd. v. Quigg, 706 F. Supp. 1224 (E.D. Va. 1989), aff'd, 894 F. 2d 392 (Fed. Cir. 1990).

The BLA was approved on July 12, 2002, which makes the submission of the patent term extension application on September 9, 2002, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Yane A. Axelrad

Associate Director for Policy

Center for Drug Evaluation and Research

cc:

Michael D. Alexander Sanofi-Synthelabo, Inc. 9 Great Valley Parkway Malvern, PA 19355

03E-0249

LET 2